CIK 0001766140 · <br>Emerging growth company
Unicycive Therapeutics, Inc.
Sign in to watch- Ticker
- UNCY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813638692
- Phone
- 650-384-0642
- Business address
- 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
- Former names
- Unicycive Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-15 | Gupta Shalabh K. CEO | Grant or award · Stock Options | +1,319,583 | 6,206,637 | ||
| 2023-09-05 | Laumas Sandeep Director | Grant or award · Stock Options | +189,236 | 200,864 | ||
| 2023-09-05 | Kenkare-Mitra Sara Director | Grant or award · Stock Options | +180,000 | 180,000 | ||
| 2023-09-05 | Ryan John L Director | Grant or award · Stock Options | +112,147 | 123,775 | ||
| 2023-09-05 | Aggarwal Gaurav Director | Grant or award · Stock Options | +180,000 | 180,000 | ||
| 2023-08-28 | Gupta Pramod EVP, Pharmaceuticals and BD | Grant or award · Stock Options | +1,355,000 | 1,574,862 | ||
| 2023-08-28 | Gupta Shalabh K. CEO | Grant or award · Stock Options | +4,684,775 | 4,988,798 | ||
| 2023-08-28 | Townsend John Chief Financial Officer | Grant or award · Stock Options | +570,329 | 647,190 | ||
| 2023-08-28 | Jermasek Douglas EVP of Corporate Strategy | Grant or award · Stock Options | +1,355,000 | 1,510,000 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion | +3,470,152 | 3,470,152 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Series A-1 Preferred Stock | −8,077 | $1,000.00 | $8.1M | 0 |
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Series A-2 Preferred Stock | +13,429,000 | 13,429,000 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Tranche A Warrants (right to buy) | +12,802,388 | 12,802,388 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Tranche B Warrants (right to buy) | +11,638,534 | 11,638,534 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Tranche C Warrants (right to buy) | +18,621,655 | 18,621,655 | ||
| 2023-07-11 | Jermasek Douglas EVP of Corporate Strategy | Option exercise | +104,612 | 175,012 | ||
| 2023-07-11 | Jermasek Douglas EVP of Corporate Strategy | Option exercise · Series A-1 Convertible Preferred Stock | −50 | $1,000.00 | $50K | 0 |
| 2023-07-11 | Jermasek Douglas EVP of Corporate Strategy | Option exercise · Warrant (right to buy | +79,252 | 79,252 | ||
| 2023-07-11 | Jermasek Douglas EVP of Corporate Strategy | Option exercise · Warrant (right to buy) | +72,047 | 72,047 | ||
| 2023-07-11 | Jermasek Douglas EVP of Corporate Strategy | Option exercise · Warrant (right to buy) | +115,275 | 115,275 |
Page 3 of 5 · 84 trades